Seto K, Haneda M, Masago K, et al. - In order to determine treatment of choice, researchers identify V600E and non-V600E mutations in non-small cell lung cancer, especially about the assay performance for non-V600E mutations. In the present study, they analyzed 117 tumors with BRAF mutations, including 30 with non-V600E mutations, using BRAF mutation-specific immunohistochemistry (IHC). Including two compound mutations, none of the tumors with non-V600E mutations, revealed a positive reaction. Moreover, except for one case, all V600E mutations were positive with combined BRAF V600E and K601_W604 deletion. The data approved that the BRAF V600E mutation-specific IHC is specific without any cross-reactions to non-V600E mutations, implying that this assay can be a beneficial screening tool in clinical practice.